

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Todd W. Seeley
 Filed : February 27, 2002
 For : huBUB3 GENE INVOLVED IN HUMAN CANCERS



Docket No. : PP-01406.004 / 200130.438D1
 Date : February 27, 2002

Box Patent Application
 Commissioner for Patents
 U.S. Patent and Trademark Office
 P.O. Box 2327
 Arlington, VA 22202

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicant wishes to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicant does not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicant's duty to disclose all information he is aware of which is believed relevant to the examination of the above-identified application, applicant believes that his invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jane E.R. Potter

Registration No. 33,332

JEP:sfl

Enclosures:

Postcard

Forms PTO-1449 (2 Sheets)

Cited References (17)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\SHANEL\257093_1.DOC

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PP-01406.004/200130.438D1	EXPRESS MAIL NO. EL755724263US
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT Todd W. Seeley	
		FILING DATE February 27, 2002	GROUP ART UNIT Not yet assigned

10/08/00
10/08/00
02/27/02

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,283,173	02/01/94	Fields et al.	435	6	
	AB	5,518,911	05/21/96	Abo et al.	435	194	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AC	WO 93/19752	10/14/93	WIPO		
	AD	WO 96/09835	04/04/96	WIPO		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AE	Database EMBL ID No. HS1249493, AC. No. AA449311, June 10, 1997.
	AF	Database EMBL ID No. HS1229812, AC. No. AA430092, May 25, 1997.
	AG	Database EMBL AC. No. P97397, May 1, 1997.
	AH	Database EMBL ID No. MMU67327, AC. No. U67327, January 19, 1997.
	AI	Hoyt et al., "S. cerevisiae Genes Required for Cell Cycle Arrest in Response to Loss of Microtubule Function," <i>Cell</i> 66: 507-517, 1991.
	AJ	Kalitsis et al., "Bub3 gene disruption in mice reveals essential mitotic spindle checkpoint function during early embryogenesis," <i>Gene & Development</i> 14(18):227-2282, September 15, 2000.
	AK	Martinez-Exposito et al., "Retention of the Bub3 checkpoint protein on lagging chromosomes," <i>P.N.A.S. USA</i> 96(15):8493-8498, July 20, 1999.
	AL	Ouyang et al., "Human Bub1: A Putative Spindle Checkpoint Kinase Closely Linked to Cell Proliferation," <i>Cell Growth & Differentiation</i> 9: 877-885, 1998.
	AM	Pangilinan et al., "Mammalian BUB1 Protein Kinases: Map Positions and <i>in Vivo</i> Expression," <i>Genomics</i> 46: 379-388, 1997.
	AN	Roberts et al., "The <i>Saccharomyces cerevisiae</i> Checkpoint Gene <i>BUB1</i> Encodes a Novel Protein Kinase," <i>Molecular And Cellular Biology</i> 14(12): 8282-8290, 1994.
	AO	Seeley et al., "Phosphorylation of human MAD1 by the BUB1 kinase <i>in vitro</i> ," <i>Biochem. Biophys. Res. Commun.</i> 257(2):589-595, April 13, 1999.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PP-01406.004/200130.438D1		EXPRESS MAIL NO. EL755724263US	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANT Todd W. Seeley			
				FILING DATE February 27, 2002		GROUP ART UNIT Not yet assigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BL					
	BM					
	BN					
	BO					
	BP					

OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
	BQ	Taylor and McKeon, "Kinetochore Localization of Murine Bub1 Is Required for Normal Mitotic Timing and Checkpoint Response to Spindle Damage," <i>Cell</i> 89: 727-735, 1997.		
	BR	Taylor et al., "The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase," <i>J. Cell Biology</i> 142(1):1-11, July 13, 1998.		
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">EXAMINER</td> <td style="width: 50%;">DATE CONSIDERED</td> </tr> </table>			EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED			

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).